Efficacy and Safety of Ixekizumab in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Paediatric Patients with Moderate-to-Severe Plaque Psoriasis (IXORA-PEDS).
CONCLUSIONS: IXE was superior to placebo in the treatment of moderate-to-severe paediatric psoriasis and the safety profile was generally consistent with that observed in adults.
PMID: 32316070 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Paller AS, Seyger MMB, MagariƱos GA, Bagel J, Pinter A, Cather J, Keller S, Capriles CR, Lima RG, Gallo G, Little CA, Edson-Heredia E, Li L, Xu W, Papp K, IXORA-PEDS study group Tags: Br J Dermatol Source Type: research